7 Physical Clues You Could Have Depression
Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU
News
Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more
Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients
News
New data from the GALLIUM Phase 3 trial (NCT01332968) shows that follicular lymphoma patients who progress within two years of immunochemotherapy have a 26-fold increased risk of death, compared to those ... Read more
Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017
News
Bayer will present long-term safety and efficacy data from the CHRONOS-1 trial of Aliqopa (copanlisib) in patients with indolent lymphomas at the American Society of Hematology (ASH) 2017 Annual Meeting ... Read more
How to Manage Cancer-Related Fatigue
MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL
News
The U.S. Food and Drug Administration has granted breakthrough therapy designation to MorphoSys‘ MOR208 – in combination with Revlimid (lenalidomide) – for the treatment of adult patients with relapsed or refractory diffuse ... Read more
Novartis Asks FDA to Approve Kymriah for Difficult-to-treat DLBCL
News
Novartis has asked U.S. regulators to expand their approval of Kymriah (tisagenlecleucel) to include the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL. The Food ... Read more
The Lymphoma Association Explains What Lymphoma Is
FDA Grants Accelerated Approval to Calquence for Mantle Cell Lymphoma
News
The U.S. Food and Drug Administration has approved AstraZeneca‘s Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA’s accelerated ... Read more
7 Recipes Every Cancer Patient Should Try
Health Canada OKs Imbruvica for Treating Chronic Graft-Versus-Host Disease
News
Janssen‘s Imbruvica (ibrutinib) has been approved by Health Canada for treating chronic graft-versus-host disease (cGVHD), a life-threatening condition that some patients develop after a stem cell transplant. Following a priority ... Read more